News

Marc Robillard will present Tagworks at the 24th BioEquity Europe on May 14 at 11:30 in San Sebastián, Spain.

We are pleased to announce the recent appointments of Maria V. Cincotta as our VP of Clinical Operations & Program Management and Tu-Anh T. Bui as our VP of CMC & Technical Operations.

The 17th Annual European Life Sciences CEO Forum will take place on the 28th - 29th February 2024 back at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week.

The 42nd Annual Healthcare Conference will take place on January 8-11, 2024 in San Francisco, CA.

The World ADC San Diego Antibody-drug Conjugate Conference will take place from October 16-19, 2023.

A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.

Read the article on Biopharmadive

By BioWorld Twelve years on from spinning out of Philips Healthcare, Tagworks Pharmaceuticals BV has raised $65 million in a series A round to take a new generation of antibody-drug conjugates (ADCs) based on click chemistry into the clinic. Read more.

By BioCentury Netherlands-based Tagworks is using click chemistry to simultaneously accomplish on-target activation of ADCs and off-target deactivation of radiopharmaceuticals. After spinning out of Philips Healthcare in 2011, the company has announced a $65 million series A round co-led by Ysios Capital and Gilde Healthcare. Download the complete article here.

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals Proceeds will be used to advance the lead program, a …